德展健康(000813.SZ):參股子公司合作研發項目取得相關批件
格隆匯 4 月 16日丨德展健康(000813.SZ)公佈,公司於2021年4月15日收到公司參股子公司北京東方略生物醫藥科技股份有限公司(“東方略”)的吿知函,東方略於近日收到中國人類遺傳資源管理辦公室的正式批件(國科遺辦審字[2021]GH0973號),同意東方略開展VGX-3100與器械CELLECTRATM 5PSP聯合治療HPV-16和/或HPV-18相關宮頸高度鱗狀上皮內病變(HSIL)(“本項目”)的三期臨牀試驗。
鑑於東方略已經獲得國藥品監督管理局關於本項目三期臨牀試驗的臨牀批件,在國內開展臨牀試驗所需的行政審批已全部通過,東方略將於近期正式啟動國內三期臨牀試驗的患者入組工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.